Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 24
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Arch Dis Child Educ Pract Ed ; 108(2): 104-108, 2023 04.
Artículo en Inglés | MEDLINE | ID: mdl-35701075

RESUMEN

Much is reported in the literature about the transmission and presentation of Chlamydia trachomatis conjunctival infection in the neonate; however, there is a paucity of information available on infection in the older pre-pubertal child (>3 years of age). We present the case of a 7-year-old girl, referred for assessment at the sexual assault referral centre following the diagnosis of unilateral C. trachomatis conjunctivitis. This child underwent a rigorous multiagency child protection process, with input from medical professionals, social services and the police to investigate the possibility of child sexual abuse (CSA). However, a group consensus was reached that non-sexual close contact transfer of C. trachomatis from the mother was the most likely mode of transmission and cause of infection. We aim to take the reader through the complex path to this conclusion, the approach to sexually transmitted infections and potential CSA and what is currently known about chlamydial conjunctivitis in children beyond the neonatal period.


Asunto(s)
Abuso Sexual Infantil , Infecciones por Chlamydia , Conjuntivitis , Recién Nacido , Femenino , Niño , Humanos , Chlamydia trachomatis , Infecciones por Chlamydia/diagnóstico , Infecciones por Chlamydia/tratamiento farmacológico , Conjuntivitis/diagnóstico , Abuso Sexual Infantil/diagnóstico , Madres
2.
J Allergy Clin Immunol ; 141(2): 704-717.e5, 2018 02.
Artículo en Inglés | MEDLINE | ID: mdl-28601685

RESUMEN

BACKGROUND: Gain-of-function (GOF) mutations in signal transducer and activator of transcription 1 (STAT1) cause susceptibility to a range of infections, autoimmunity, immune dysregulation, and combined immunodeficiency. Disease manifestations can be mild or severe and life-threatening. Hematopoietic stem cell transplantation (HSCT) has been used in some patients with more severe symptoms to treat and cure the disorder. However, the outcome of HSCT for this disorder is not well established. OBJECTIVE: We sought to aggregate the worldwide experience of HSCT in patients with GOF-STAT1 mutations and to assess outcomes, including donor engraftment, overall survival, graft-versus-host disease, and transplant-related complications. METHODS: Data were collected from an international cohort of 15 patients with GOF-STAT1 mutations who had undergone HSCT using a variety of conditioning regimens and donor sources. Retrospective data collection allowed the outcome of transplantation to be assessed. In vitro functional testing was performed to confirm that each of the identified STAT1 variants was in fact a GOF mutation. RESULTS: Primary donor engraftment in this cohort of 15 patients with GOF-STAT1 mutations was 74%, and overall survival was only 40%. Secondary graft failure was common (50%), and posttransplantation event-free survival was poor (10% by 100 days). A subset of patients had hemophagocytic lymphohistiocytosis before transplant, contributing to their poor outcomes. CONCLUSION: Our data indicate that HSCT for patients with GOF-STAT1 mutations is curative but has significant risk of secondary graft failure and death.


Asunto(s)
Mutación con Ganancia de Función , Predisposición Genética a la Enfermedad , Enfermedad Injerto contra Huésped/genética , Enfermedad Injerto contra Huésped/mortalidad , Trasplante de Células Madre Hematopoyéticas , Factor de Transcripción STAT1/genética , Aloinjertos , Supervivencia sin Enfermedad , Femenino , Enfermedad Injerto contra Huésped/inmunología , Humanos , Masculino , Estudios Retrospectivos , Factores de Riesgo , Factor de Transcripción STAT1/inmunología , Tasa de Supervivencia
3.
BMC Ophthalmol ; 18(Suppl 1): 218, 2018 Sep 14.
Artículo en Inglés | MEDLINE | ID: mdl-30255794

RESUMEN

BACKGROUND: Diffuse unilateral subacute neuroretinitis (DUSN) is a rare cause of posterior uveitis in the United Kingdom. It typically presents unilaterally in children and young adults but rarely bilateral cases have been reported. It is also rare to have multiple worms in the same eye causing the clinical picture. In this article, we present a challenging case of DUSN in a young girl unresponsive to conventional treatments suggesting the possibility of multiple worms being present in the same eye. CASE PRESENTATION: An 8-year-old girl presented with a 2-month history of headaches. On occasions the headaches were associated with redness and watering of her left eye. She denied any visual loss or visual symptoms. Her visual acuity was reduced to 6/30 in her left eye. Fundal examination revealed a unilateral chorioretinitis. Investigation did not reveal a specific cause for the chorioretinitis. Over 15 months her visual acuity improved to 6/9 but the fundal appearance changed and a diagnosis of DUSN was made. She was treated with focal laser, systemic anti-helminthic and immunosuppressive treatments but continued to develop new, active areas of chorioretinitis, raising the possibility of multiple worms in the sub-retinal space. There is also a concern as to other central nervous system (CNS) involvement given her significant and ongoing headaches. CONCLUSION: We present a challenging case of DUSN in a young girl; a condition that remains rare in the UK. She was unresponsive to both focal laser and systemic anti-helminthic and immunosuppressive treatments suggesting the possibility of multiple worms being present in the sub-retinal space. This case highlights the difficulties often encountered in the treatment of DUSN, even when a worm can be identified. Her visual prognosis is poor as there was ongoing recurrence of active chorioretinitis.


Asunto(s)
Coriorretinitis/diagnóstico , Infecciones Parasitarias del Ojo/diagnóstico , Infecciones por Nematodos/diagnóstico , Enfermedad Aguda , Albendazol/uso terapéutico , Antiprotozoarios/uso terapéutico , Niño , Coriorretinitis/parasitología , Coriorretinitis/terapia , Terapia Combinada , Infecciones Parasitarias del Ojo/parasitología , Infecciones Parasitarias del Ojo/terapia , Femenino , Glucocorticoides/uso terapéutico , Humanos , Coagulación con Láser/métodos , Láseres de Semiconductores/uso terapéutico , Infecciones por Nematodos/parasitología , Infecciones por Nematodos/terapia , Tomografía de Coherencia Óptica
6.
Alzheimer Dis Assoc Disord ; 28(1): 30-5, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-23842286

RESUMEN

The understanding of how cerebrovascular disease (CVD) contributes to dementia is hampered by a lack of agreed and validated pathologic methods to accord weight to the contribution of different aspects of CVD to dementia. A previous study from the Oxford Project to Investigate Memory and Ageing (OPTIMA) validated a scheme for assessing the contribution of subcortical small vessel disease (SVD) toward dementia in the elderly by showing a significant inverse relationship between the severity of SVD and cognition in subjects without any other dementia pathology using this method. In the present paper, the method has been used to assess severity of SVD in 161 cases of neuropathologically confirmed Alzheimer disease. The results showed there was no relationship between the SVD score and cognitive scores acquired in the last 2 years of life. SVD scores were significantly related to age (P<0.0017) and were slightly but significantly higher in females than males (P<0.049). SVD scores were not related to blood pressure at entry to OPTIMA and were significantly lower when compared with the cohort of OPTIMA cases with only CVD (mean 5.06 ± 1.85 vs. 5.9 ± 2.67; P<0.0065). We conclude that when Alzheimer disease pathology is present in elderly subjects, it overwhelms the modest contribution that SVD makes to cognitive impairment.


Asunto(s)
Envejecimiento/patología , Enfermedad de Alzheimer/patología , Encéfalo/patología , Trastornos Cerebrovasculares/patología , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Pruebas Neuropsicológicas
7.
Stroke ; 44(11): 3063-70, 2013 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-24021688

RESUMEN

BACKGROUND AND PURPOSE: White matter changes (WMC) are a common finding on brain imaging and are associated with an increased risk of ischemic stroke. They are most frequent in small vessel stroke; however, in the absence of comparisons with normal controls, it is uncertain whether WMC are also more frequent than expected in other stroke subtypes. Therefore, we compared WMC in pathogenic subtypes of ischemic stroke versus controls in a population-based study. METHODS: We evaluated the presence and severity of WMC on computed tomography and on magnetic resonance brain imaging using modified Blennow/Fazekas scale and age-related white matter changes scale, respectively, in a population-based study of patients with incident transient ischemic attack or ischemic stroke (Oxford Vascular Study) and in a study of local controls (Oxford Project to Investigate Memory and Ageing) without history of transient ischemic attack or ischemic stroke, with stratification by stroke pathogenesis (Trial of Org10172 in Acute Stroke Treatment classification). RESULTS: Among 1601 consecutive eligible patients with first-ever ischemic events, 1453 patients had computed tomography brain imaging, 562 had magnetic resonance imaging, and 414 patients had both. Compared with 313 controls (all with computed tomography and 131 with magnetic resonance imaging) and after adjustment for age, sex, diabetes mellitus, and hypertension, moderate/severe WMC (age-related white matter changes scale) were more frequent in patients with small vessel events (odds ratio, 3.51 [95% confidence interval, 2.13-5.76]; P<0.0001) but not in large artery (odds ratio, 1.03 [95% confidence interval, 0.64-1.67]), cardioembolic (odds ratio, 0.87 [95% confidence interval, 0.56-1.34]), or undetermined (odds ratio, 0.90 [95% confidence interval, 0.62-1.30]) subtypes. Results were consistent for ischemic stroke and transient ischemic attack, for other scales, and for magnetic resonance imaging and computed tomography separately. CONCLUSIONS: In contrast to small vessel ischemic events, WMC were not independently associated with other pathogenic subtypes, suggesting that WMC are unlikely to be an independent risk factor for nonsmall vessel events.


Asunto(s)
Isquemia Encefálica/patología , Encéfalo/patología , Ataque Isquémico Transitorio/patología , Accidente Cerebrovascular/patología , Anciano , Anciano de 80 o más Años , Encéfalo/diagnóstico por imagen , Isquemia Encefálica/diagnóstico por imagen , Estudios de Casos y Controles , Complicaciones de la Diabetes/patología , Femenino , Humanos , Hipertensión/complicaciones , Ataque Isquémico Transitorio/diagnóstico por imagen , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Oportunidad Relativa , Factores de Riesgo , Accidente Cerebrovascular/diagnóstico por imagen , Tomografía Computarizada por Rayos X
8.
Ann Vasc Surg ; 25(2): 248-55, 2011 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-21131173

RESUMEN

BACKGROUND: Major vascular surgery involves a high risk of major cardiovascular morbidity and mortality. A method of predicting perioperative myocardial events is required. Preoperative B-type natriuretic peptide (BNP) has been evaluated for this purpose. The aims of this study were to determine the postoperative course of BNP levels and correlate these levels with the outcome. METHODS: The present study included 45 patients undergoing major vascular surgery. These patients further underwent serial venous blood sampling for troponin-T and BNP and serial electrocardiograms, pre- and postoperatively (immediately postoperatively and at days 1 through 4). RESULTS: Of the 45 patients, seven suffered myocardial damage, as defined by troponin-T. An immediate postoperative BNP (cutoff, 171 pg/mL) was better able to predict cardiac damage (p = 0.027) than BNP levels preoperatively (cutoff, 281 pg/mL, p = 0.042) and on day 1 postoperatively (cutoff, 182 pg/mL, p = 0.032). Only the preoperative BNP levels showed an effect on survival. Patients with a preoperative BNP >281 pg/mL had a mean survival of 12.7 months, as compared with 17.6 months for patients with a BNP <281 pg/mL, p = 0.044. CONCLUSION: Preoperative BNP is an accurate determinant of postoperative cardiac morbidity and all cause survival, with BNP in the immediate postoperative period being an even more accurate predictor of cardiac events. An immediate postoperative BNP might help risk stratify patients for the next 72 hours in the perioperative period (and maybe longer).


Asunto(s)
Cardiopatías/diagnóstico , Péptido Natriurético Encefálico/sangre , Procedimientos Quirúrgicos Vasculares , Anciano , Anciano de 80 o más Años , Biomarcadores/sangre , Distribución de Chi-Cuadrado , Electrocardiografía , Femenino , Cardiopatías/sangre , Cardiopatías/etiología , Cardiopatías/mortalidad , Humanos , Estimación de Kaplan-Meier , Masculino , Persona de Mediana Edad , Periodo Posoperatorio , Valor Predictivo de las Pruebas , Periodo Preoperatorio , Estudios Prospectivos , Curva ROC , Medición de Riesgo , Factores de Riesgo , Escocia , Factores de Tiempo , Troponina T/sangre , Procedimientos Quirúrgicos Vasculares/efectos adversos , Procedimientos Quirúrgicos Vasculares/mortalidad
9.
Arch Dis Child ; 106(7): 680-686, 2021 07.
Artículo en Inglés | MEDLINE | ID: mdl-33172887

RESUMEN

BACKGROUND: Studies based on molecular testing of oral/nasal swabs underestimate SARS-CoV-2 infection due to issues with test sensitivity, test timing and selection bias. The objective of this study was to report the presence of SARS-CoV-2 antibodies, consistent with previous infection. DESIGN: This multicentre observational cohort study, conducted between 16 April to 3 July 2020 at 5 UK sites, recruited children of healthcare workers, aged 2-15 years. Participants provided blood samples for SARS-CoV-2 antibody testing and data were gathered regarding unwell contacts and symptoms. RESULTS: 1007 participants were enrolled, and 992 were included in the final analysis. The median age of participants was 10·1 years. There were 68 (6.9%) participants with positive SARS-CoV-2 antibody tests indicative of previous SARS-CoV-2 infection. Of these, 34/68 (50%) reported no symptoms prior to testing. The presence of antibodies and the mean antibody titre was not influenced by age. Following multivariable analysis four independent variables were identified as significantly associated with SARS-CoV-2 seropositivity: known infected household contact OR=10.9 (95% CI 6.1 to 19.6); fatigue OR=16.8 (95% CI 5.5 to 51.9); gastrointestinal symptoms OR=6.6 (95% CI 3.0 to 13.8); and changes in sense of smell or taste OR=10.0 (95% CI 2.4 to 11.4). DISCUSSION: Children demonstrated similar antibody titres in response to SARS-CoV-2 irrespective of age. Fatigue, gastrointestinal symptoms and changes in sense of smell or taste were the symptoms most strongly associated with SARS-CoV-2 antibody positivity. TRIAL REGISTRATION NUMBER: NCT0434740.


Asunto(s)
Anticuerpos Antivirales/sangre , COVID-19 , Enfermedades Gastrointestinales , Trastornos del Olfato , SARS-CoV-2 , COVID-19/diagnóstico , COVID-19/epidemiología , COVID-19/inmunología , Prueba Serológica para COVID-19/métodos , Prueba Serológica para COVID-19/estadística & datos numéricos , Niño , Femenino , Enfermedades Gastrointestinales/diagnóstico , Enfermedades Gastrointestinales/virología , Humanos , Masculino , Trastornos del Olfato/diagnóstico , Trastornos del Olfato/virología , SARS-CoV-2/inmunología , SARS-CoV-2/aislamiento & purificación , Estudios Seroepidemiológicos , Evaluación de Síntomas/métodos , Evaluación de Síntomas/estadística & datos numéricos , Reino Unido/epidemiología
11.
BMJ Open Qual ; 9(2)2020 05.
Artículo en Inglés | MEDLINE | ID: mdl-32423972

RESUMEN

Developing respiratory complications postoperatively is one of the major determinants of longer hospital stay, morbidity, mortality and increased healthcare costs. The incidence of postoperative respiratory complications varies from 1% to 23%. Given that postoperative respiratory complications are relatively common and costly, there have been various studies which look at ways to reduce the risk of these occurring. One such protocol is the ICOUGH bundle which stands for Incentive spirometry, Coughing and deep breathing, Oral care, patient Understanding, Getting out of bed and Head of bed elevation. This has been adapted locally to the Coughing and deep breathing, Oral care, patient Understanding, Getting out of bed and Head of bed elevation (COUGH) bundle which consists of these components excluding incentive spirometry. Within our surgical high dependency unit (HDU), the COUGH bundle should be implemented in patients who have a moderate or high risk of developing postoperative respiratory complications with an Assess Respiratory Risk in Surgical Patients in Catalonia (ARISCAT) score of 26 or above. Studies have shown that the ICOUGH bundle has reduced rates of pneumonia and unplanned intubation in general surgical and vascular patients. Baseline data taken from surgical HDU showed that the COUGH bundle was not well implemented. One out of eight patients who had an ARISCAT score greater than 26 had the COUGH bundle implemented on admission to the unit. Three out of eight patients had the ARISCAT score documented in their admission medical review. One patient who should have received the bundle, but did not, developed a hospital acquired pneumonia postoperatively. To address this issue, we aimed to increase awareness surrounding the COUGH bundle and to increase the number of patients who had the COUGH bundle started on admission. This quality improvement project had four cycles (plan, do, study, act) and after these, 100% of patients who had an ARISCAT score of 26 or more had the COUGH bundle implemented.


Asunto(s)
Paquetes de Atención al Paciente/normas , Complicaciones Posoperatorias/mortalidad , Terapia Respiratoria/normas , Enfermedades Respiratorias/mortalidad , Tos , Femenino , Humanos , Enfermedad Iatrogénica/epidemiología , Enfermedad Iatrogénica/prevención & control , Tiempo de Internación/estadística & datos numéricos , Masculino , Persona de Mediana Edad , Paquetes de Atención al Paciente/métodos , Paquetes de Atención al Paciente/estadística & datos numéricos , Neumonía/epidemiología , Neumonía/prevención & control , Mejoramiento de la Calidad/estadística & datos numéricos , Terapia Respiratoria/métodos , Terapia Respiratoria/estadística & datos numéricos , Enfermedades Respiratorias/epidemiología , Enfermedades Respiratorias/etiología , Escocia/epidemiología
12.
BMJ Open ; 10(11): e041661, 2020 11 19.
Artículo en Inglés | MEDLINE | ID: mdl-33444212

RESUMEN

BACKGROUND: A novel coronavirus SARS-CoV-2 has been responsible for a worldwide pandemic. Children typically have very mild, or no, symptoms of infection. This makes estimations of seroprevalence in children difficult. Research is therefore required to determine the seroprevalence of SARS-CoV-2 antibodies in children. The primary objective of this study is to report the seroprevalence of SARS-CoV-2 IgM and/or IgG antibodies in healthy children at baseline, 2 months and 6 months. This is the only longitudinal UK study of seroprevalence in an exclusively paediatric population. Determining the changing seroprevalence is of vital public health importance and can help inform decisions around the lifting of paediatric specific social distancing measures such as school closures and the cancellation of routine paediatric hospital services. METHODS AND ANALYSIS: 1000 healthy children of healthcare workers aged between 2 and 15 years will be recruited from five UK sites (Belfast, Cardiff, Glasgow, London and Manchester). The children will undergo phlebotomy at baseline, 2 months and 6 months to measure IgM and/or IgG positivity to SARS-CoV-2. A sample size of 675 patients is required to detect a 5% change in seroprevalence at each time point assuming an alpha of 0.05 and a beta of 0.2. Adjusted probabilities for the presence of IgG and/or IgM antibodies and of SARS-CoV-2 infection will be reported using logistic regression models where appropriate. ETHICS AND DISSEMINATION: Ethical approval was obtained from the London - Chelsea Research Ethics Committee (REC Reference-20/HRA/1731) and the Belfast Health & Social Care Trust Research Governance (Reference 19147TW-SW). Results of this study will be made available as preprints and submitted for publication in peer-reviewed journals. TRIAL REGISTRATION NUMBER: NCT0434740; Results.


Asunto(s)
Anticuerpos Antivirales/sangre , Personal de Salud , SARS-CoV-2/inmunología , Estudios Seroepidemiológicos , Adolescente , Niño , Preescolar , Femenino , Humanos , Estudios Longitudinales , Masculino , Pandemias , Estudios Prospectivos , Reino Unido/epidemiología
13.
J Alzheimers Dis ; 67(1): 327-341, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-30636741

RESUMEN

Biomarker discovery is a major need for earlier dementia diagnosis. We evaluated a plasma signature of amyloid, metallo-proteinases (MMPs), and inflammatory markers in a cohort of at-risk individuals and individuals clinically diagnosed with probable Alzheimer's disease (pAD). Using multiplex arrays, we measured Aß40, Aß42, MMP-1, MMP-3, MMP-9, IFN-γ, TNF-α, IL-6, IL-8, and IL-10 in plasma from 107 individuals followed every 6 months for 3 years. Final diagnoses included: pAD (n = 28), mild cognitive impairment (MCI, n = 30), subjective memory impairment (SMI, n = 30), and asymptomatic (NCI, n = 19). Blood was drawn at final follow-up. We used linear and logistic regressions to examine biomarker associations with prior known decline on the Montreal Cognitive Assessment (MoCA) and the Cambridge Cognitive Examination (CAMCOG); as well disease progression by the time of blood-draw. We derived a biomarker composite from the individual markers, and tested its association with a clinical diagnosis of pAD. Lower Aß40 and Aß42 and higher IL-8, IL-10, and TNF-α were associated with greater cognitive decline per the MoCA and CAMCOG. MMP-3 was higher in SMI, MCI, and pAD than NCI. Whereas the other investigative molecules did not differ between groups, composite scores-created using MoCA/CAMCOG-based trends in Aß40, Aß42, MMP-1, MMP-3, IL-8, IL-10, and TNF-α- were associated with a final diagnosis of pAD (c-statistic 0.732 versus 0.602 for age-sex alone). Thus, plasma amyloid, MMP, and inflammatory biomarkers demonstrated differences in individuals with cognitive deterioration and/or progression to MCI/pAD. Our findings support studying these markers earlier in the continuum of probable AD as well as in specific dementias.


Asunto(s)
Enfermedad de Alzheimer/sangre , Disfunción Cognitiva/sangre , Demencia/sangre , Factores de Edad , Anciano , Anciano de 80 o más Años , Enfermedad de Alzheimer/psicología , Péptidos beta-Amiloides/sangre , Biomarcadores/sangre , Disfunción Cognitiva/psicología , Estudios de Cohortes , Demencia/psicología , Diagnóstico Precoz , Femenino , Humanos , Inflamación/sangre , Masculino , Metaloproteasas/sangre , Pruebas Neuropsicológicas , Estudios Retrospectivos , Factores Sexuales
14.
Respir Med ; 101(10): 2084-90, 2007 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-17631991

RESUMEN

INTRODUCTION: The COPD airway is infiltrated with CD8+ T cells, which has led to a virus being implicated in its pathogenesis. Some investigators have suggested a role for the persistence of the adenovirus E1A in bronchial epithelial cells. We examined respiratory tract specimens from COPD patients for the presence of E1A DNA and mRNA using real-time PCR. METHODS: Nucleic acid extraction was performed on sputum specimens from patients with COPD. Copy numbers for GAPDH, and adenovirus 5 E1A DNA and mRNA were determined using a quantitative real-time PCR assay. All samples were screened for the adenovirus hexon gene using nested PCR. RESULTS: One hundred and seventy-one patients, 80 male, aged 68.9+/-9.8 years with COPD were recruited. One hundred and thirty-six were seen during an exacerbation when admitted to hospital, 33 of whom were reviewed when clinically stable along with an additional 35 stable COPD patients. Ten patients in the exacerbation group were positive for the adenovirus hexon gene (7%), as were four in the stable group (6%). Only two patients in the exacerbation group were positive for adenovirus 5 E1A. Only one patient in the stable COPD group had detectable E1A DNA/mRNA and also tested positive for the adenovirus hexon gene. CONCLUSION: Adenovirus is detected in similar frequencies in exacerbated and stable COPD patients. Adenovirus E1A DNA is infrequently detected in respiratory secretions from patients with COPD. Our data suggest that the persistence of adenovirus 5 E1A in lung cells of sputum samples in patients with COPD occurs infrequently.


Asunto(s)
Infecciones por Adenoviridae/complicaciones , Adenoviridae/aislamiento & purificación , Enfermedad Pulmonar Obstructiva Crónica/virología , Proteínas E1A de Adenovirus/metabolismo , Anciano , Femenino , Humanos , Masculino , Reacción en Cadena de la Polimerasa , Mucosa Respiratoria/virología , Esputo/virología , Latencia del Virus
15.
Ann Clin Transl Neurol ; 3(10): 812-818, 2016 10.
Artículo en Inglés | MEDLINE | ID: mdl-27752516

RESUMEN

We have developed a novel real-time quaking-induced conversion RT-QuIC-based assay to detect alpha-synuclein aggregation in brain and cerebrospinal fluid from dementia with Lewy bodies and Parkinson's disease patients. This assay can detect alpha-synuclein aggregation in Dementia with Lewy bodies and Parkinson's disease cerebrospinal fluid with sensitivities of 92% and 95%, respectively, and with an overall specificity of 100% when compared to Alzheimer and control cerebrospinal fluid. Patients with neuropathologically confirmed tauopathies (progressive supranuclear palsy; corticobasal degeneration) gave negative results. These results suggest that RT-QuiC analysis of cerebrospinal fluid is potentially useful for the early clinical assessment of patients with alpha-synucleinopathies.

16.
Pediatr Infect Dis J ; 34(2): 121-4, 2015 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-25126855

RESUMEN

BACKGROUND: Approximately 5-6% of all infective episodes in neonatal intensive care unit (NICU) are of viral origin. Previous studies suggest that human parechovirus (HPeV) infection presents most commonly in term infants, as a sepsis-like syndrome in which meningoencephalitis is prominent. Our aim was to study the infection rate and associated features of HPeV. METHODS: Blood samples were taken from NICU babies older than 48 hours, who were being investigated for late onset sepsis. Clinical and laboratory data were collected at the time of the suspected sepsis episode. Samples were tested using universal primers and probe directed at the 5'-untranslated region of the HPeV genome by reverse transcriptase polymerase chain reaction (RT-PCR). Results were confirmed by electrophoresis and DNA sequencing. RESULTS: HPeV was detected in 11 of 84 samples (13%). These infants had a mean [interquartile range (IQR)] gestational age of 28.9 (26.9-30.6) weeks and mean birth weight of 1.26 (SD = 0.72) kg. The median day of presentation was 16 (IQR: 11-27). These characteristics were similar to the infants without positive viral detection. Six infants presented with respiratory signs. One infant presented with signs of meningitis. Six of the 11 episodes of HPeV infection occurred during the winter months (December to February). No HPeV positive infants had abnormal findings on their 28-day cranial ultrasound examination. CONCLUSIONS: We found an HPeV infection rate of 13% in infants being tested for late onset sepsis. HPeV should be considered as a possible cause of sepsis-like symptoms in preterm infants.


Asunto(s)
Parechovirus/aislamiento & purificación , Infecciones por Picornaviridae/epidemiología , Sepsis/epidemiología , Estudios de Cohortes , Electroforesis , Humanos , Recién Nacido , Cuidado Intensivo Neonatal , Masculino , Infecciones por Picornaviridae/virología , Prevalencia , Estudios Prospectivos , ARN Viral/genética , ARN Viral/aislamiento & purificación , Sepsis/virología , Análisis de Secuencia de ADN
17.
PLoS One ; 10(8): e0136472, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26305781

RESUMEN

OBJECTIVE: To compare the use of a generic molecular assay to 'standard' investigations used to assist the diagnosis of late onset bacterial sepsis in very low birth weight infants (VLBW, <1500 g). METHODS: VLBW infants, greater than 48 hours of age, who were clinically suspected to have sepsis were investigated using standard tests (full blood count, C-reactive protein (at presentation) and blood culture), in addition, blood was taken for a universal molecular assay (16S rRNA reverse transcriptase PCR) for comparison. Clinical data were recorded during the suspected infection episode. A validated sepsis score (NEO-KISS) was used to retrospectively determine the presence of sepsis (independent of blood culture). The performance of each of the tests were compared by sensitivity, specificity, positive/negative likihood ratios (+/-LR) and postive/negative predictive values (PPV/NPV). RESULTS: Sixty-five babies with suspected clinical sepsis were prospectively included. The performance indicators are presented with 95% confidence limits. For the detection of bacteria, blood culture had sensitivity of 0.57 (0.34-0.78), specificity of 0.45 (0.30-0.61); +LR of 1.05 (0.66-1.66) and-LR of 0.94 (0.52-1.7); PPV of 33.3 (18.56-50.97) and NPV of 68.97 (49.17-87.72). Serum CRP had sensitivity of 0.92 (0.64-1) and specificity of 0.36 (0.17-0.59); +LR of 1.45 (1-2.1) and-LR of 0.21 (0.03-1.5); PPV of 44.46 (26.6-66.6) and NPV of 88.9 (51.8-99.7). The universal molecular assay had sensitivity of 0.76 (0.53-0.92), specificity of 0.95 (0.85-0.99); +LR of 16.8 (4.2-66.3) and-LR of 0.25 (0.1-0.5); PPV of 88.9 (65.3-98.6) and NPV of 89.4 (76.9-96.5). CONCLUSIONS: In VLBW infants this universal molecular assay performed better in the diagnosis of late onset sepsis (LOS) than blood culture and CRP. Further development is required to explore and improve the performance of the assay in real-time diagnosis.


Asunto(s)
Pruebas Hematológicas/métodos , Recién Nacido de muy Bajo Peso/sangre , Sepsis/sangre , Sepsis/diagnóstico , Edad de Inicio , Proteína C-Reactiva/metabolismo , Femenino , Humanos , Recién Nacido , Masculino , ARN Ribosómico 16S/genética , Curva ROC
18.
Brain Pathol ; 25(1): 51-62, 2015 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-25521177

RESUMEN

Cerebral amyloid angiopathy (CAA) is of increasing clinical and research interest as the ability to detect it and its consequences by neuroimaging in living subjects has advanced. There is also increasing interest in understanding its possible role in the development of intracerebral hemorrhage, Alzheimer's disease (AD) and vascular dementia. In this article, the literature on this subject is reviewed and novel findings relating CAA to subcortical white matter damage in 224 subjects in the Oxford project to Investigate Memory and Ageing (OPTIMA) are reported. The relationship between CAA and subcortical tissue damage in the OPTIMA subjects was found to be critically dependent on ApoE genotype, there being a positive relationship between measures of CAA and subcortical small vessel disease in ApoEε4 carriers and a significant negative relationship in ApoEε2 carriers. These findings draw attention, as have many other studies, to the importance of ApoE genotype as a major risk factor not only for dementia but also for damage to blood vessels in the aging brain.


Asunto(s)
Encéfalo/patología , Angiopatía Amiloide Cerebral/patología , Demencia/genética , Demencia/patología , Leucoencefalopatías/patología , Anciano , Anciano de 80 o más Años , Animales , Apolipoproteínas E/genética , Angiopatía Amiloide Cerebral/complicaciones , Angiopatía Amiloide Cerebral/epidemiología , Angiopatía Amiloide Cerebral/genética , Demencia/complicaciones , Demencia/epidemiología , Demencia/terapia , Femenino , Humanos , Leucoencefalopatías/genética , Estudios Longitudinales , Masculino
19.
PLoS One ; 10(1): e0114050, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25625488

RESUMEN

With the exception of ApoE4, genome-wide association studies have failed to identify strong genetic risk factors for late-onset Alzheimer's disease, despite strong evidence of heritability, suggesting that many low penetrance genes may be involved. Additionally, the nature of the identified genetic risk factors and their relation to disease pathology is also largely obscure. Previous studies have found that a cancer-associated variant of the cell cycle inhibitor gene p21cip1 is associated with increased risk of Alzheimer's disease. The aim of this study was to confirm this association and to elucidate the effects of the variant on protein function and Alzheimer-type pathology. We examined the association of the p21cip1 variant with Alzheimer's disease and Parkinson's disease with dementia. The genotyping studies were performed on 719 participants of the Oxford Project to Investigate Memory and Ageing, 225 participants of a Parkinson's disease DNA bank, and 477 participants of the Human Random Control collection available from the European Collection of Cell Cultures. The post mortem studies were carried out on 190 participants. In the in-vitro study, human embryonic kidney cells were transfected with either the common or rare p21cip1 variant; and cytometry was used to assess cell cycle kinetics, p21cip1 protein expression and sub-cellular localisation. The variant was associated with an increased risk of Alzheimer's disease, and Parkinson's disease with dementia, relative to age matched controls. Furthermore, the variant was associated with an earlier age of onset of Alzheimer's disease, and a more severe phenotype, with a primary influence on the accumulation of tangle pathology. In the in-vitro study, we found that the SNPs reduced the cell cycle inhibitory and anti-apoptotic activity of p21cip1. The results suggest that the cancer-associated variant of p21cip1 may contribute to the loss of cell cycle control in neurons that may lead to Alzheimer-type neurodegeneration.


Asunto(s)
Enfermedad de Alzheimer/genética , Inhibidor p21 de las Quinasas Dependientes de la Ciclina/genética , Edad de Inicio , Enfermedad de Alzheimer/mortalidad , Enfermedad de Alzheimer/patología , Apoptosis , Ciclo Celular , Supervivencia sin Enfermedad , Frecuencia de los Genes , Estudios de Asociación Genética , Predisposición Genética a la Enfermedad , Células HEK293 , Humanos , Estimación de Kaplan-Meier , Polimorfismo de Nucleótido Simple , Lóbulo Temporal/metabolismo , Lóbulo Temporal/patología , Población Blanca , Proteínas tau/metabolismo
20.
Acta Neuropathol Commun ; 1: 3, 2013 May 08.
Artículo en Inglés | MEDLINE | ID: mdl-24252508

RESUMEN

BACKGROUND: The development of disease-modifying therapies for Alzheimer's disease is hampered by our lack of understanding of the early pathogenic mechanisms and the lack of early biomarkers and risk factors.We have documented the expression pattern of mTOR regulated genes in the frontal cortex of Alzheimer's disease patients. We have also examined the functional integrity of mTOR signaling in peripheral lymphocytes in Alzheimer's disease patients relative to healthy controls. RESULTS: In the brain mTOR is seen to control molecular functions related to cell cycle regulation, cell death and several metabolic pathways. These downstream elements of the mTOR signaling cascade are deregulated in the brain of Alzheimer's disease patients well before the development of pathology. This dysregulation of the mTOR downstream signaling cascade is not restricted to the brain but appears to be systemic and can be detected in peripheral lymphocytes as a reduced Rapamycin response. CONCLUSIONS: The dysfunction of the signaling pathways downstream of mTOR may represent a risk factor for Alzheimer's disease and is independent of the ApoE status of the patients.We have also identified the molecular substrates of the beneficial effects of Rapamycin on the nervous system. We believe that these results can further inform the development of clinical predictive tests for the risk of Alzheimer's disease in patients with mild cognitive impairment.


Asunto(s)
Enfermedad de Alzheimer/metabolismo , Lóbulo Frontal/metabolismo , Linfocitos/metabolismo , Serina-Treonina Quinasas TOR/metabolismo , Anciano , Anciano de 80 o más Años , Enfermedad de Alzheimer/epidemiología , Enfermedad de Alzheimer/genética , Apolipoproteínas E/genética , Ciclo Celular/efectos de los fármacos , Ciclo Celular/fisiología , Células Cultivadas , Femenino , Expresión Génica/efectos de los fármacos , Humanos , Masculino , Persona de Mediana Edad , Inhibidores de Proteínas Quinasas/farmacología , Factores de Riesgo , Transducción de Señal , Sirolimus/farmacología , Serina-Treonina Quinasas TOR/antagonistas & inhibidores
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA